Drug intelligence / Profile preview

Zerun 9-valent HPV vaccine

Development stage
Phase 3
Lead developer
Shanghai Zerun Biotechnology
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

Zerun 9-valent HPV vaccine is an investigational **recombinant, Pichia pastoris-expressed human papillomavirus L1 virus-like particle vaccine** developed by Shanghai Zerun Biotechnology for prevention of disease caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. It is designed to induce prophylactic neutralizing immune responses against these HPV types, which are associated with cervical, vulvar, vaginal, and anal cancers, as well as genital warts. The product has progressed through Phase I evaluation and has been studied in a Phase III active-controlled immunogenicity and safety trial versus Gardasil 9 in healthy females aged 16 to 26 years. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03900572))

Other names
Zerun HPV-99-valent HPV recombinant vaccinerecombinant human papillomavirus nonavalent virus-like particle vaccine
02

Targets

HPV L1 (Human papillomavirus L1 capsid protein)HPV11 L1HPV16 (Human papillomavirus type 16)Human papillomavirus type 18 major capsid protein L1HPV31 L1HPV45 L1HPV52 L1 (Human papillomavirus type 52 major capsid protein L1)HPV58 L1 (Human papillomavirus type 58 major capsid protein L1)HPV6 L1 (Human papillomavirus type 6 major capsid protein L1)

Beyond the preview

Go deeper on Zerun 9-valent HPV vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zerun 9-valent HPV vaccine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call